Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pasina

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Obesity Research & Clinical Practice|February 8, 2025
Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysisMarina Azab, Luca Pasina
Drug Design, Development and Therapy|April 7, 2010
New atypical antipsychotics for schizophrenia: iloperidoneSilvio Caccia, Luca Pasina, Alessandro Nobili
European Journal of Internal Medicine|June 26, 2016
Biological agents and biosimilars: Essential information for the internistLuca Pasina, Gianluigi Casadei, Alessandro Nobili
Drugs & Aging|April 15, 2025
Comparison of Anticholinergic Burden Scales and Their Association with Cognitive and Functional Impairment in Older Adults: A Cross-Sectional Study Using the REPOSI DatabaseAlessio Novella, Marina Azab, Luca Pasina, et al.
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|October 21, 2024
FORTA Score and Negative Outcomes in Older Adults: Insights from Italian Internal Medicine WardsMarina Azab, Alessio Novella, Luca Pasina
Neuropsychiatric Disease and Treatment|May 10, 2012
Critical appraisal of lurasidone in the management of schizophreniaSilvio Caccia, Luca Pasina, Alessandro Nobili
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|April 27, 2025
Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: analysis of The FDA Adverse Event Reporting System (FAERS)Alessio Novella, Chiara Elli, Luca Pasina
Pharmacoepidemiology and Drug Safety|October 24, 2020
Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based studyLuca Pasina, Ugo Lucca, Mauro Tettamanti
European Journal of Clinical Pharmacology|November 30, 2023
Serotonin syndrome: A pharmacovigilance comparative study of drugs affecting serotonin levelsChiara Elli, Alessio Novella, Luca Pasina
European Journal of Internal Medicine|January 3, 2013
How pre-marketing data can be used for predicting the weight of drug interactions in clinical practiceSilvio Caccia, Luca Pasina, Alessandro Nobili
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Obesity Research & Clinical Practice|February 8, 2025
Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysisMarina Azab, Luca Pasina
Drug Design, Development and Therapy|April 7, 2010
New atypical antipsychotics for schizophrenia: iloperidoneSilvio Caccia, Luca Pasina, Alessandro Nobili
European Journal of Internal Medicine|June 26, 2016
Biological agents and biosimilars: Essential information for the internistLuca Pasina, Gianluigi Casadei, Alessandro Nobili
Drugs & Aging|April 15, 2025
Comparison of Anticholinergic Burden Scales and Their Association with Cognitive and Functional Impairment in Older Adults: A Cross-Sectional Study Using the REPOSI DatabaseAlessio Novella, Marina Azab, Luca Pasina, et al.
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|October 21, 2024
FORTA Score and Negative Outcomes in Older Adults: Insights from Italian Internal Medicine WardsMarina Azab, Alessio Novella, Luca Pasina
Neuropsychiatric Disease and Treatment|May 10, 2012
Critical appraisal of lurasidone in the management of schizophreniaSilvio Caccia, Luca Pasina, Alessandro Nobili
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|April 27, 2025
Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: analysis of The FDA Adverse Event Reporting System (FAERS)Alessio Novella, Chiara Elli, Luca Pasina
Pharmacoepidemiology and Drug Safety|October 24, 2020
Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based studyLuca Pasina, Ugo Lucca, Mauro Tettamanti
European Journal of Clinical Pharmacology|November 30, 2023
Serotonin syndrome: A pharmacovigilance comparative study of drugs affecting serotonin levelsChiara Elli, Alessio Novella, Luca Pasina
European Journal of Internal Medicine|January 3, 2013
How pre-marketing data can be used for predicting the weight of drug interactions in clinical practiceSilvio Caccia, Luca Pasina, Alessandro Nobili
Pageof 9